varenicline has been researched along with Cognitive Dysfunction in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Chen, Y; Hu, X; Huang, C; Li, A; Lu, W; Qian, C; Wang, J; Zhang, Y; Zhou, Y; Zhu, S | 1 |
| Ebrahimi-Kalan, A; Farhoudi, M; Hosseini, L; Kazmi, S; Mahmoudi, J; Rahbarghazi, R; Sadigh-Eteghad, S; Seyedaghamiri, F; Shanehbandi, D | 1 |
| Benson, C; Dark, F; De Monte, V; Gore-Jones, V; Kisely, S; Melo, CD; Rossell, SL; Shah, S; Siskind, D; Tanzer, T | 1 |
| Golebiowska, J; Nikiforuk, A; Popik, P; Potasiewicz, A | 1 |
| Kaakkola, S; Tuominen, R | 1 |
| Barr, MS; Dermody, SS; George, TP; Kozak, K; Rabin, RA; Tyndale, RF; Zack, M | 1 |
2 review(s) available for varenicline and Cognitive Dysfunction
| Article | Year |
|---|---|
Varenicline for cognitive impairment in people with schizophrenia: systematic review and meta-analysis.
Topics: Cognitive Dysfunction; Humans; Nicotinic Agonists; Schizophrenia; Varenicline | 2020 |
[Nicotine and neurologic diseases--even a noxious substance may possess beneficial properties].
Topics: Alzheimer Disease; Ataxia; Benzazepines; Cognitive Dysfunction; Epilepsy, Frontal Lobe; Humans; Mutation; Nicotine; Nicotinic Agonists; Parkinson Disease; Quinoxalines; Receptors, Nicotinic; Tobacco Use Cessation Devices; Varenicline | 2013 |
1 trial(s) available for varenicline and Cognitive Dysfunction
| Article | Year |
|---|---|
Effects of varenicline on cognitive function in non-smokers with schizophrenia.
Topics: Adult; Cognitive Dysfunction; Double-Blind Method; Humans; Memory, Short-Term; Nicotinic Agonists; Non-Smokers; Schizophrenia; Space Perception; Treatment Outcome; Varenicline; Visual Perception | 2018 |
3 other study(ies) available for varenicline and Cognitive Dysfunction
| Article | Year |
|---|---|
Varenicline improved laparotomy-induced cognitive impairment by restoring mitophagy in aged mice.
Topics: Aging; Animals; Apoptosis; Behavior, Animal; Cognitive Dysfunction; Disease Models, Animal; eIF-2 Kinase; Laparotomy; Male; Maze Learning; Mice, Inbred C57BL; Mitochondria; Mitophagy; Neurons; Neuroprotective Agents; Oxidative Stress; Perioperative Care; Postoperative Cognitive Complications; STAT3 Transcription Factor; tau Proteins; Varenicline | 2022 |
Varenicline improves cognitive impairment in a mouse model of mPFC ischemia: The possible roles of inflammation, apoptosis, and synaptic factors.
Topics: Animals; Anxiety; Apoptosis; Behavior, Animal; Brain Ischemia; Cognitive Dysfunction; Disease Models, Animal; Mice; Neuroinflammatory Diseases; Nicotinic Agonists; Prefrontal Cortex; Synapses; Varenicline | 2022 |
Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2- and α 7-nicotinic acetylcholine receptors.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Cognition; Cognitive Dysfunction; Disease Models, Animal; Drug Monitoring; Nicotinic Agonists; Rats; Receptors, Nicotinic; Schizophrenia; Treatment Outcome; Varenicline | 2018 |